Clinical Trial Update: Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Enfortumab Vedotin in previously treated locally advanced or metastatic pancreatic cancer (EPIC) is active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING